GSK Adds Detailed Clinical Trial Data to Multi-Sponsor Request System as Part of Commitment to Data Transparency
GlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system (clinicalstudydatarequest.com) that includes studies from multiple organisations.
Last year, GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results. More than 450 studies have now been made available on the new site. GSK’s patient-level data transparency commitments remain unchanged through the new multi-sponsor request system:
◾GSK is continuing to post studies going back to the formation of GSK in 2000.
◾Studies are made available once a medicine has been approved by regulators or terminated from development and the study has been accepted for publication (studies that do not progress to publication will also be included).
◾Researchers can ask about the availability of data they are interested in from studies not yet listed on the site.
◾The arm’s length review panel who have been reviewing proposals through GSK’s site since May 2013 will continue its role and will now review proposals that include studies from other sponsors. Up to 30 November 2013, 16 requests for data had been received by the review panel. Twelve requests had been approved, with four being processed. None had been turned down.
GSK will regularly add studies to the site. The next major update, when additional new and historic studies will be added, is planned for Q1 2014.
James Shannon, GSK’s Chief Medical Officer, said: “Our commitment to transparency of clinical trial data reflects our wish to help advance scientific understanding and enable the scientific community to learn from the research we have undertaken. Enabling researchers to request the studies they are interested in from multiple organisations through one system will, we hope, help further research.
“Our ultimate aim remains unchanged and that is to see a broad system developed that brings together data from many organisations and is also run by an independent third party who would be responsible for managing the review of research proposals. This initiative is an important step towards that aim.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance